These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1038 related articles for article (PubMed ID: 9181234)

  • 21. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytokines as an adjuvant to tumor vaccines: efficacy of local methods of delivery.
    Kurane S; Arca MT; Aruga A; Krinock RA; Krauss JC; Chang AE
    Ann Surg Oncol; 1997; 4(7):579-85. PubMed ID: 9367025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bryostatin 1-activated T cells can traffic and mediate tumor regression.
    Tuttle TM; Bethke KP; Inge TH; McCrady CW; Pettit GR; Bear HD
    J Surg Res; 1992 Jun; 52(6):543-8. PubMed ID: 1528028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adoptive immunotherapy with cells from tumor-draining lymph nodes activated and expanded in vitro.
    Haynes C; Graham L; Bear HD
    Methods Cell Biol; 2024; 183():355-380. PubMed ID: 38548419
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon.
    Abdel-Wahab Z; Dar M; Osanto S; Fong T; Vervaert CE; Hester D; Jolly D; Seigler HF
    Cancer Gene Ther; 1997; 4(1):33-41. PubMed ID: 9012449
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor.
    Chang AE; Li Q; Bishop DK; Normolle DP; Redman BD; Nickoloff BJ
    Hum Gene Ther; 2000 Apr; 11(6):839-50. PubMed ID: 10779161
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ability of low-dose cyclophosphamide to overcome metastasis-induced immunosuppression.
    Tuttle TM; Fleming MD; Hogg PS; Inge TH; Bear HD
    Ann Surg Oncol; 1994 Jan; 1(1):53-8. PubMed ID: 7834429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
    Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
    Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced efficacy of allogeneic versus syngeneic fibroblasts modified to secrete cytokines as a tumor vaccine adjuvant.
    Aruga A; Aruga E; Chang AE
    Cancer Res; 1997 Aug; 57(15):3230-7. PubMed ID: 9242454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of immune reactivity in the lymph nodes draining a murine melanoma engineered to elaborate interleukin-4.
    Krauss JC; Strome SE; Chang AE; Shu S
    J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):77-84. PubMed ID: 7804530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GM-CSF-transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune-compromised mice.
    Kumar R; Yoneda J; Fidler IJ; Dong Z
    J Leukoc Biol; 1999 Jan; 65(1):102-8. PubMed ID: 9886252
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression.
    Aruga A; Aruga E; Cameron MJ; Chang AE
    J Leukoc Biol; 1997 Apr; 61(4):507-16. PubMed ID: 9103238
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy for lung metastases of murine renal cell carcinoma: synergy between radiation and cytokine-producing tumor vaccines.
    Nishisaka N; Maini A; Kinoshita Y; Yasumoto R; Kishimoto T; Jones RF; Morse P; Hillman GG; Wang CY; Haas GP
    J Immunother; 1999 Jul; 22(4):308-14. PubMed ID: 10404432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sentinel node mapping identifies vaccine-draining lymph nodes with tumor-specific immunological activity.
    Chin CS; Bear HD
    Ann Surg Oncol; 2002; 9(1):94-103. PubMed ID: 11829435
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged culture of vaccine-primed lymphocytes results in decreased antitumor killing and change in cytokine secretion.
    Sussman JJ; Parihar R; Winstead K; Finkelman FD
    Cancer Res; 2004 Dec; 64(24):9124-30. PubMed ID: 15604282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
    Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
    Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine.
    Kayaga J; Souberbielle BE; Sheikh N; Morrow WJ; Scott-Taylor T; Vile R; Chong H; Dalgleish AG
    Gene Ther; 1999 Aug; 6(8):1475-81. PubMed ID: 10467372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic and local paracrine cytokine therapies using transduced tumor cells are synergistic in treating intracranial tumors.
    Thompson RC; Pardoll DM; Jaffee EM; Ewend MG; Thomas MC; Tyler BM; Brem H
    J Immunother Emphasis Tumor Immunol; 1996 Nov; 19(6):405-13. PubMed ID: 9041459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.